feed,title,long_url,short_url
Benzinga,"Y-mAbs Therapeutics Plans To Deprioritize Omburtamab For Pediatric Cancer, Cuts One Third Of Workforce",https://benzinga.com/general/biotech/23/01/30294905/y-mabs-therapeutics-plans-to-deprioritize-omburtamab-for-pediatric-cancer-cuts-one-third-of-workf,https://da.gd/NDdZV
